Mersana Therapeutics Inc (MRSN)


Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Mersana Therapeutics Inc chart...

About the Company

mersana is rewriting the rules for immunoconjugate therapies by leveraging our fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients’ lives. our fleximer platform allows us to custom design an adc with specific properties to overcome limitations of current adc approaches and increase the drug’s chances of effectively attacking a particular cancer. we engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, mersana’s adc therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today’s cancer treatments.

CEO

Anna Protopapas

Exchange

NASDAQ

Website

http://www.mersana.com/

$3M

Total Revenue

255

Employees

$608M

Market Capitalization

-2.98

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $MRSN News

Mersana Therapeutics, Inc. (MRSN) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

27d ago, source: Hosted on MSN

For the last reported quarter, it was expected that Mersana Therapeutics, Inc. Would post a loss of $0.31 per share when it actually produced a loss of $0.35, delivering a surprise of -12.90%.

Mersana Therapeutics, Inc. (MRSN) Q4 2023 Earnings Call Transcript

19d ago, source: Seeking Alpha

Good morning, and welcome to the Mersana Therapeutics Fourth Quarter 2023 Conference Call and Webcast. Currently, all participants are in listen-only mode. There will be a question-and-answer ...

Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results

20d ago, source: Business Insider

Feb. 28, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates ...

Mersana Therapeutics Inc (MRSN) Reports Fourth Quarter and Full Year 2023 Financial Results

20d ago, source: Yahoo Finance

Warning! GuruFocus has detected 7 Warning Signs with MRSN. Mersana Therapeutics Inc (NASDAQ:MRSN) released its 8-K filing on February 28, 2024, providing a business update and announcing its ...

Mersana Therapeutics Inc MRSN

18d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Q4 2023 Mersana Therapeutics Inc Earnings Call

19d ago, source:

Good morning, and welcome to the Mersana Therapeutics fourth-quarter 2023 conference call and webcast. (Operator Instructions) Please note this call is being recorded. I would now like to turn the ...

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2023 Earnings Call Transcript

19d ago, source: Insider Monkey

Mersana Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome to the Mersana ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...